X

Drug Profile

MRT 6160

Alternative Names: MRT-6160

Latest Information Update: 22 Aug 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Monte Rosa Therapeutics
Class Antineoplastics; Antirheumatics; Small molecules
Mechanism of Action Proto oncogene protein c vav degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Autoimmune disorders

Most Recent Events

19 Aug 2024 Phase-I clinical trials in Autoimmune disorders (In volunteers) (PO)
19 Aug 2024 Monte Rosa Therapeutics plans a phase-I trial in healthy volunteers in August 2024
08 Aug 2024 US FDA accepts IND application for MRT 6160 in Autoimmune disorders

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com